+Vote!
Medical News Today (Free subscription) | 05/10/2008
Exelixis, Inc. (Nasdaq:EXEL) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases.
+Vote!
Red Orbit (Free subscription) | 03/10/2008
Exelixis, a development-stage biotechnology company, has submitted an investigational new drug application to the FDA for XL888, a novel anticancer compound.
+Vote!
Red Orbit (Free subscription) | 03/10/2008
Exelixis, Inc. (Nasdaq:EXEL) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound.
+Vote!
Planet Intertwingly (Free subscription) | 04/09/2008
It is interesting to see the notion of tech platforms play out in other fields. Specifically, the biotech field is all abuzz on platforms. For example Exelixis' oncology platform built on kinase inhibitors.Having a validated drug discovery platform is the first and most important criterion for defining a good platform company. The platform is typically comprised of a combination of technology, experienced...
+Vote!
Seeking Alpha (Free subscription) | 03/09/2008
Ohad Hammer submits: The pharmaceutical industry is in the midst of a severe innovation crisis, where more R&D money results in less approved drugs. In parallel, sales of most traditional blockbusters are being cannibalized by generic competition, forcing the big pharmas to exploit new concepts and rush new drug candidates to their pipelines. Nearly half of all drugs that are expected to enter the...
+Vote!
EuroInvestor.co.uk (Free subscription) | 29/08/2008
First graph, second sentence of release should read: Mr. Karbe will discuss updates to the company ’ s development pipeline and corporate strategy (sted Dr. Sca.. - Read more
+Vote!
Business Wire (Free subscription) | 25/08/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, Executive Vice President and Chief Financial Officer of Exelixis, will present at
+Vote!
Seeking Alpha (Free subscription) | 06/08/2008
Exelixis Inc. (EXEL) Q2 2008 Earnings Call Complete Story »
+Vote!
bizjournals (Free subscription) | 05/08/2008
Exelixis Inc. on Tuesday reported a second quarter loss of $45.1 million, or 43 cents a share, compared to $28.6 million, or 29 cents a share for the same period last year. (EXEL)
+Vote!
Business Wire (Free subscription) | 05/08/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the second quarter ended June 30, 2008.
+Vote!
Business Wire (Free subscription) | 28/07/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under
+Vote!
Business Wire (Free subscription) | 22/07/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2008 financial results on Tuesday, August 5, 2008, after the markets close.
+Vote!
The San Francisco Business Times (Free subscription) | 21/07/2008
Exelixis Inc. started a late-stage clinical trial of a treatment for medullary thyroid cancer. (EXEL)
